Pieris Pharmaceuticals, Inc

(NASDAQ:PIRS)

Latest On Pieris Pharmaceuticals, Inc (PIRS):

Date/Time Type Description Signal Details
2023-05-17 06:56 ESTNewsPieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed SitesN/A
2023-05-10 19:27 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57MN/A
2023-05-10 19:27 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 17:07 ESTNewsPieris Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-18 01:10 ESTNewsPieris spikes 11% on data for gastric cancer candidateN/A
2023-03-29 16:58 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.45 beats by $0.02, revenue of $25.9M misses by $0.67MN/A
2023-03-29 16:57 ESTNewsPieris stock slumps ~15% after FY22 sees fall in revenueN/A
2023-03-29 16:57 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call TranscriptN/A
2023-03-29 16:57 ESTNewsPieris Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-29 01:52 ESTNewsPieris Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-10 13:01 ESTNewsPieris to get $5M as Seagen starts dosing in phase 1 trial of cancer drugN/A
2022-11-02 21:54 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $5.37M beats by $0.86MN/A
2022-11-02 21:53 ESTNewsPieris Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-02 21:53 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call TranscriptN/A
2022-08-07 06:05 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 15:23 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77MN/A
2022-08-04 15:23 ESTNewsPieris Pharma stock falls ~7% on Q2 earnings miss, discontinuation of a phase 2 studyN/A
2022-08-04 00:43 ESTNewsPieris Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-05-25 22:37 ESTNewsPieris Pharmaceuticals (PIRS) Investor presentations - SlideshowN/A
2022-05-12 03:29 ESTNewsPieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 07:53 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.07 beats by $0.05, revenue of $10.99M misses by $0.31MN/A
2022-05-10 11:52 ESTNewsPieris Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-02 05:15 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-01 11:20 ESTNewsPieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97MN/A
2022-01-15 19:11 ESTNewsPieris Is A Biotech To Watch With Extensive Pipeline And Key PartnershipsN/A
2022-01-14 12:12 ESTNewsPieris Pharmaceuticals begins dosing in phase 2 gastric cancer studyN/A
2022-01-10 07:21 ESTNewsPieris: Early Stage Developer Of Novel Asset ClassN/A
2021-10-28 00:12 ESTNewsProgress At Pieris PharmaceuticalsN/A
2021-10-06 15:02 ESTNewsPieris Pharmaceuticals promotes from within for CFO positionN/A
2021-08-04 13:22 ESTNewsPieris Pharmaceuticals EPS beats by $0.02, beats on revenueN/A
2021-07-21 19:46 ESTNewsPieris Pharma jumps on collaboration with GenentechN/A
2021-07-21 19:31 ESTNewsPieris Pharmaceuticals shares rise after FDA orphan drug status for cinrebafuspN/A
2021-07-21 19:31 ESTNewsPieris Pharma stock soars 17% on development plans for PRS-220 in lung disease; secures $17M grantN/A
2021-07-21 19:29 ESTNewsJefferies boosts price target for Pieris citing plans to develop 'long COVID' candidateN/A
2021-03-31 06:35 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-30 11:17 ESTNewsPieris Pharmaceuticals EPS in-line, misses on revenueN/A
2021-03-25 19:17 ESTNewsSeagen invests $13M in Pieris, inks deal for PRS-343 + Tuksya in gastric cancerN/A
2021-01-29 12:20 ESTAnalyst RatingThe Analyst Target Price has increased from $7.67 to $9.Buy
2021-01-19 16:23 ESTNewsFDA lifts partial hold on Pieris' early-stage study of lead drugN/A
2020-11-26 21:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 04:54 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 00:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:50 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 12:35 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 12:30 ESTAnalyst RatingThe Analyst Target Price has decreased from $8 to $7.67.Neutral
2020-11-05 12:57 ESTEarnings EstimateAn EPS average of -$0.19 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-05 12:34 ESTNewsMore on Pieris Pharmaceuticals Q3 earnings missN/A
2020-11-05 12:33 ESTNewsPieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-04 09:00 ESTNewsPieris Pharmaceuticals EPS misses by $0.13, misses on revenueN/A
2020-09-30 14:32 ESTNewsSeeking Alpha Catalyst WatchN/A

About Pieris Pharmaceuticals, Inc (PIRS):

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

PIRS Quotes by TradingView

See Advanced Chart

General

  • Name Pieris Pharmaceuticals, Inc
  • Symbol PIRS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 114
  • Last Split Factor2:1
  • Last Split Date2014-12-08
  • Fiscal Year EndDecember
  • IPO Date2015-04-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.pieris.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 3.17
  • Price/Book (Most Recent Quarter) 3.38
  • Enterprise Value Revenue 1.82
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.19
  • Profit Margin -53%
  • Operating Margin -51%
  • Return on Assets -12%
  • Return on Equity -73%
  • Revenue 44.72 million
  • Earnings Per Share -$0.77
  • Revenue Per Share $0.83
  • Gross Profit 46.28 million
  • Quarterly Earnings Growth -80.6%
View More

Highlights

  • Market Capitalization 150.9 million
  • EBITDA -42862000
  • PE Ratio -1.02
  • Analyst Target Price $9
  • Book Value Per Share $0.78
View More

Share Statistics

  • Shares Outstanding 55.97 million
  • Shares Float 43.18 million
  • % Held by Insiders 9%
  • % Held by Institutions 61.05%
  • Shares Short 2.51 million
  • Shares Short Prior Month 2.32 million
  • Short Ratio 4.62
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.29
  • 52 Week High $3.64
  • 52 Week Low $1.8
  • 50 Day Moving Average 2.76
  • 200 Day Moving Average 2.65
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Pieris Pharmaceuticals, Inc (PIRS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Pieris Pharmaceuticals, Inc (PIRS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-04$2.94 million-$0.26-$0.25-4%
2020-06-302020-08-10$11.25 million-$0.09-$0.2157.81%
2020-03-312020-05-11$13.26 million-$0.07-$0.1861.11%
2019-12-312020-03-12$17.27 million-$0.06-$0.2475%
2019-09-302019-11-12$15.13 million-$0.05-$0.2277.27%
2019-06-302019-08-09$5.33 million-$0.24-$0.20-22.01%
2019-03-312019-05-10$8.55 million-$0.20-$0.18-11.11%
2018-12-312019-03-18$4.91 million-$0.21-$0.18-16.67%
2018-09-302018-11-07$8.35 million-$0.11-$0.1315.38%
2018-06-302018-08-09$11.69 million$-0.00-$0.1296.7%
2018-03-312018-05-10$4.15 million-$0.17-$0.11-59.33%
2017-12-312018-03-09$18.15 million$0.18-$0.05485.44%
2017-09-302017-11-08$3.93 million-$0.16-$0.2123.81%
2017-06-302017-08-09$1.85 million-$0.23-$0.20-15%
2017-03-312017-05-10$1.34 million-$0.19-$0.205%
2016-12-312017-03-23$2.73 million-$0.16-$0.160%
2016-09-302016-11-09$785000-$0.14-$0.140%
2016-06-302016-08-10$1.07 million-$0.14-$0.12-13.54%
2016-03-312016-05-11$1.25 million-$0.10-$0.04-185.71%
2015-12-312016-03-22$2.14 million-$0.07-$0.1344%
2015-09-302015-11-11$416000-$0.10-$0.119.09%
2015-06-302015-08-13$159000-$0.12-$0.137.69%
2015-03-312015-05-13$218000-$0.09
2014-12-312015-03-25$5.37 million-$0.14

Pieris Pharmaceuticals, Inc (PIRS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Pieris Pharmaceuticals, Inc (PIRS) Chart:

Pieris Pharmaceuticals, Inc (PIRS) News:

Below you will find a list of latest news for Pieris Pharmaceuticals, Inc (PIRS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Pieris Pharmaceuticals, Inc (PIRS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-202.50CALL0 00TRUE00
2024-12-2050CALL0 00TRUE00
2024-12-207.50CALL0 00TRUE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 00FALSE00
2024-12-207.50PUT0 00FALSE00

Latest PIRS Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$1.65
Jun 13, 2022 7:58 PM EST100$1.645
Jun 13, 2022 7:59 PM EST7$1.64
Jun 13, 2022 7:59 PM EST100$1.65
Jun 13, 2022 7:59 PM EST12$1.64

Pieris Pharmaceuticals, Inc (PIRS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000037/0001583648-20-000037-index.htm
2019-12-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1583648/000000000019016221/0000000000-19-016221-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000083423720008213/0000834237-20-008213-index.htm
2018-11-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000092189518003155/0000921895-18-003155-index.htm
2019-02-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000092189519000178/0000921895-19-000178-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000092189519000449/0000921895-19-000449-index.htm
2019-09-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000092189519002390/0000921895-19-002390-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000092189519002391/0000921895-19-002391-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000092189520000558/0000921895-20-000558-index.htm
2020-02-19SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000092189520000591/0000921895-20-000591-index.htm
2019-11-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000093583619000593/0000935836-19-000593-index.htm
2018-09-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1583648/000094787118000781/0000947871-18-000781-index.htm
2019-08-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1583648/000119312519218074/0001193125-19-218074-index.htm
2019-11-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1583648/000119312519289380/0001193125-19-289380-index.htm
2019-12-04S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1583648/000119312519306299/0001193125-19-306299-index.htm
2019-12-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1583648/000119312519311451/0001193125-19-311451-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000119312520099499/0001193125-20-099499-index.htm
2020-08-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1583648/000119312520215001/0001193125-20-215001-index.htm
2018-09-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018003936/0001562180-18-003936-index.htm
2018-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018003953/0001562180-18-003953-index.htm
2018-10-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018004279/0001562180-18-004279-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018004280/0001562180-18-004280-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018004281/0001562180-18-004281-index.htm
2018-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218018004310/0001562180-18-004310-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000566/0001562180-19-000566-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000570/0001562180-19-000570-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000571/0001562180-19-000571-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000572/0001562180-19-000572-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000577/0001562180-19-000577-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000578/0001562180-19-000578-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000579/0001562180-19-000579-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019000580/0001562180-19-000580-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019001486/0001562180-19-001486-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019001487/0001562180-19-001487-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019001488/0001562180-19-001488-index.htm
2019-04-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019002447/0001562180-19-002447-index.htm
2019-07-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004075/0001562180-19-004075-index.htm
2019-08-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004129/0001562180-19-004129-index.htm
2019-08-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004130/0001562180-19-004130-index.htm
2019-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004581/0001562180-19-004581-index.htm
2019-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004584/0001562180-19-004584-index.htm
2019-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019004585/0001562180-19-004585-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218019005263/0001562180-19-005263-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000617/0001562180-20-000617-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000619/0001562180-20-000619-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000620/0001562180-20-000620-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000621/0001562180-20-000621-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000622/0001562180-20-000622-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000623/0001562180-20-000623-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000624/0001562180-20-000624-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020000625/0001562180-20-000625-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020001864/0001562180-20-001864-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020001865/0001562180-20-001865-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020001866/0001562180-20-001866-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004686/0001562180-20-004686-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004687/0001562180-20-004687-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004688/0001562180-20-004688-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004689/0001562180-20-004689-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004691/0001562180-20-004691-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004692/0001562180-20-004692-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004693/0001562180-20-004693-index.htm
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004695/0001562180-20-004695-index.htm
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000156218020004696/0001562180-20-004696-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000058/0001583648-18-000058-index.htm
2018-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000060/0001583648-18-000060-index.htm
2018-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000062/0001583648-18-000062-index.htm
2018-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000064/0001583648-18-000064-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000066/0001583648-18-000066-index.htm
2018-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000068/0001583648-18-000068-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000070/0001583648-18-000070-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000072/0001583648-18-000072-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364818000074/0001583648-18-000074-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000076/0001583648-18-000076-index.htm
2018-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000078/0001583648-18-000078-index.htm
2018-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364818000080/0001583648-18-000080-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000002/0001583648-19-000002-index.htm
2019-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000004/0001583648-19-000004-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000006/0001583648-19-000006-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000008/0001583648-19-000008-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/0001583648-19-000011-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000014/0001583648-19-000014-index.htm
2019-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000016/0001583648-19-000016-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000018/0001583648-19-000018-index.htm
2019-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000020/0001583648-19-000020-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364819000021/0001583648-19-000021-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000023/0001583648-19-000023-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000025/0001583648-19-000025-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000028/0001583648-19-000028-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000032/0001583648-19-000032-index.htm
2019-06-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000035/0001583648-19-000035-index.htm
2019-06-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000036/0001583648-19-000036-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000038/0001583648-19-000038-index.htm
2019-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000041/0001583648-19-000041-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000043/0001583648-19-000043-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000045/0001583648-19-000045-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364819000051/0001583648-19-000051-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000052/0001583648-19-000052-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000054/0001583648-19-000054-index.htm
2019-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000056/0001583648-19-000056-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000058/0001583648-19-000058-index.htm
2019-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000060/0001583648-19-000060-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000062/0001583648-19-000062-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000064/0001583648-19-000064-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000066/0001583648-19-000066-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000068/0001583648-19-000068-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000070/0001583648-19-000070-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000072/0001583648-19-000072-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364819000075/0001583648-19-000075-index.htm
2019-11-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1583648/000158364819000077/0001583648-19-000077-index.htm
2020-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000002/0001583648-20-000002-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000004/0001583648-20-000004-index.htm
2020-01-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000006/0001583648-20-000006-index.htm
2020-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000008/0001583648-20-000008-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000010/0001583648-20-000010-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000012/0001583648-20-000012-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/0001583648-20-000015-index.htm
2020-03-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000017/0001583648-20-000017-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000021/0001583648-20-000021-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000022/0001583648-20-000022-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000024/0001583648-20-000024-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364820000026/0001583648-20-000026-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000029/0001583648-20-000029-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000031/0001583648-20-000031-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000033/0001583648-20-000033-index.htm
2020-06-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000035/0001583648-20-000035-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000037/0001583648-20-000037-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000039/0001583648-20-000039-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000042/0001583648-20-000042-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000044/0001583648-20-000044-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364820000046/0001583648-20-000046-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000050/0001583648-20-000050-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000053/0001583648-20-000053-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000055/0001583648-20-000055-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000158364820000057/0001583648-20-000057-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1583648/000158364820000061/0001583648-20-000061-index.htm
2019-10-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000159198619000009/0001591986-19-000009-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000159198620000006/0001591986-20-000006-index.htm
2020-03-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000159198620000008/0001591986-20-000008-index.htm
2020-04-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1583648/000159198620000009/0001591986-20-000009-index.htm
2020-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000159198620000011/0001591986-20-000011-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1583648/000162828019007642/0001628280-19-007642-index.htm
2019-11-20DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1583648/000171369519000007/0001713695-19-000007-index.htm
2018-08-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1583648/999999999518002196/9999999995-18-002196-index.htm
2019-12-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1583648/999999999519002801/9999999995-19-002801-index.htm
2019-05-14CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999719004336/9999999997-19-004336-index.htm
2019-07-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999719006090/9999999997-19-006090-index.htm
2020-01-21CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999720000219/9999999997-20-000219-index.htm
2020-01-21CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999720000220/9999999997-20-000220-index.htm
2020-05-12CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999720002761/9999999997-20-002761-index.htm
2020-08-07CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1583648/999999999720004330/9999999997-20-004330-index.htm

Pieris Pharmaceuticals, Inc (PIRS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pieris Pharmaceuticals, Inc (PIRS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 9%
Institutional Ownership: 6105%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-09-14CHRISTOPHER P KIRITSYDirectorBuy5,000.005.1125,525.0010,000.00https://www.sec.gov/Archives/edgar/data/1583648/000156218018003953/0001562180-18-003953-index.htm
2019-09-06PARTNERS L P/IL BVF10% Share HolderSell25,720.004.50115,724.572,233,074.00https://www.sec.gov/Archives/edgar/data/1583648/000092189519002391/0000921895-19-002391-index.htm
2019-09-06PARTNERS L P/IL BVF10% Share HolderSell23,152.004.50104,170.112,385,055.00https://www.sec.gov/Archives/edgar/data/1583648/000092189519002391/0000921895-19-002391-index.htm
2019-09-06PARTNERS L P/IL BVF10% Share HolderSell1,128.004.505,075.32314,139.00https://www.sec.gov/Archives/edgar/data/1583648/000092189519002391/0000921895-19-002391-index.htm
2020-07-21Aquilo Capital Management, LLC10% Share HolderSell1,900,000.002.955,605,000.003,675,530.00https://www.sec.gov/Archives/edgar/data/1583648/000159198620000011/0001591986-20-000011-index.htm